ArticleInternational cancer conference journal2025

Pathologic complete response to enfortumab vedotin plus pembrolizumab in node-positive urothelial carcinoma: a case report.

Takuto Hara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.